CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 43 enrolled
Drug / intervention
Combigan Two Times Daily (BID) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02167035
NCT02167035Phase 4Completed
CompareCT.gov

Pilot Study Comparison of Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension

Cornerstone Health Care, PA·interventional·Posted Jun 18, 2014·Updated Oct 24, 2018

In Brief

A Phase 4 clinical trial evaluating Combigan Two Times Daily (BID) and Simbrinza Three Times Daily (TID) for Glaucoma and Ocular Hypertension. Completed, enrolled 43 participants across 1 site.

Detailed Summary

To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
CollaboratorsAllergan

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 18, 2014
Enrollment StartAug 1, 2014
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.0 years ago

Interventions

Combigan Two Times Daily (BID)drug

Simbrinza Three Times Daily (TID)drug